{
    "organizations": [],
    "uuid": "aa656f92dec96c6eb1dc46b164aa6fe5fff3b2b1",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-merck-co-says-us-fda-has-set-pdufa/brief-merck-co-says-u-s-fda-has-set-pdufa-date-of-sept-23-2018-idUSASC09Y5R",
    "ord_in_thread": 0,
    "title": "BRIEF-Merck & Co Says U.S. FDA Has Set PDUFA Date Of Sept. 23, 2018",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 30 (Reuters) - Merck & Co Inc:\n* FDA GRANTS PRIORITY REVIEW TO MERCK’S SBLA FOR KEYTRUDA® (PEMBROLIZUMAB) IN COMBINATION WITH PEMETREXED (ALIMTA®) AND PLATINUM CHEMOTHERAPY BASED ON RESULTS FROM PHASE 3 KEYNOTE-189 TRIAL AS FIRST-LINE TREATMENT OF METASTATIC NONSQUAMOUS NSCLC\n* MERCK & CO INC - U.S. FDA HAS SET A PDUFA DATE OF SEPT. 23, 2018 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-04-30T19:10:00.000+03:00",
    "crawled": "2018-05-01T19:50:30.021+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "merck",
        "co",
        "inc",
        "fda",
        "grant",
        "priority",
        "review",
        "merck",
        "sbla",
        "pembrolizumab",
        "combination",
        "pemetrexed",
        "platinum",
        "chemotherapy",
        "based",
        "result",
        "phase",
        "trial",
        "treatment",
        "metastatic",
        "nonsquamous",
        "nsclc",
        "merck",
        "co",
        "inc",
        "fda",
        "set",
        "pdufa",
        "date",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}